Pfizer sales of COVID-19 vaccine, pill beat forecasts as company prepares for future waves

Pfizer on Thursday reported higher-than-expected sales of its COVID-19 vaccine and Paxlovid antiviral drug in the second quarter, as slower U.S. vaccinations were offset by growth overseas, keeping it on track to reach about $100 billion in revenue this year.